NGAL and Hepcidin Levels in Hemodialysis Patients in Assiut University Hospital

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-04

Study Completion Date

2020-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the pattern of NGAL and Hepicidin in relation to anemia in End Stage Renal Disease Patients on regular hemodialysis in Assiut University Hospital and study the relation between both NGAL and Hepicidin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease

NCT04008810

Chronic Kidney Diseases CKD NGAL +4 more

COMPLETED

Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury

NCT01122225

Acute Kidney Failure

UNKNOWN

Normoalbuminuric Chronic Kidney Disease in Type 2 Diabetes

NCT04411342

Chronic Kidney Diseases

UNKNOWN

Combining CAF, L-FABP and NGAL as a Potentially Diagnostic Model for Acute Kidney Injury.

NCT04555382

Acute Kidney Injury

UNKNOWN

Usefulness of Neutrophil Gelatinase-associated Lipocalin(NGAL) to Confirm Acute Kidney Function Decrease of the Patients Who Had Non-cardiac Surgery

NCT02233010

Chronic Kidney Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with chronic kidney disease have a chronic inflammatory state, due to many factors e.g. enhancedincidence of infections, the uremic milieu, elevated levels of proinflammatory cytokines, frequent presence of widespread arteriosclerosis, etc. Iron metabolism is disturbedin chronic inflammatory diseases.AlteredNGAL levels in hemodialysis patients was probablydue to the fact that this protein was involved in ironmetabolism and suggested that NGAL might be anew tool in the assessment of iron deficiency.Another study found in multipleregression analysis that; residual renal function, hepcidin,creatinine and hsCRP were predictors of serum NGAL inhemodialyzed patients. They concluded that NGAL is highly induced in dialyzed patients and could reflect both kidney function and iron metabolism.Several studies suggested that hepcidin plays a role as anegative regulator of intestinal iron absorption and ironrelease from macrophages. Hepcidin controls intestinal ironabsorption by regulating ferroportin expression on thebasolateral membrane of enterocytes .Hepicidin is also an acute phase reactant.Both NGAL and hepcidin are elevated inchronic kidney disease,not only through ironmetabolism, but both are also associated with inflammationand may be related to anemia. Possible relationship between NGAL and hepicidin is still under study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CKD (Chronic Kidney Disease) Stage 5D

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control healthy subjects without anemia.

1. Adults \> 18 years.
2. Age and sex matched.
3. No active infection or inflammation.

NGAL and Hepcidin

Intervention Type DIAGNOSTIC_TEST

Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia

ESRD with Hgb <11 g/dl.

1. Adults \> 18 years.
2. ESRD patients on regular hemodialysis.
3. Hgb \< 11g/dl.
4. No apparent infection or inflammation.

NGAL and Hepcidin

Intervention Type DIAGNOSTIC_TEST

Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia

ESRD with Hgb ≥ 11 g/dl

1. Adults \> 18 years.
2. ESRD patients on regular hemodialysis.
3. Hgb ≥ 11g/dl.
4. No apparent infection or inflammation.

NGAL and Hepcidin

Intervention Type DIAGNOSTIC_TEST

Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.